IP Library Granted Patent US 7,919,247
Granted Patent B2
US 7,919,247 · App. 11/949,162 · Granted Apr 5, 2011

Simultaneous quantification of nucleic acids in diseased cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,919,247
App. No.
11/949,162
Granted
Apr 5, 2011
Kind
B2
Abstract

A process for assessing mitochondrial toxicity of a compound that includes contacting nucleic acids from a host with an amplification reaction mixture that contains at least two primers that provide detectable signals, wherein: a first primer provides a first detectable signal upon amplification of a host mitochondrial nucleic acid; a second primer provides a second detectable signal upon amplification of a host nuclear nucleic acid; and comparing the first and second detectable signals.

Claims (28)

1. A method for assessing mitochondrial toxicity of a compound in a living cell from a host, the method comprising:

contacting a living cell from a host with a compound;

recovering nucleic acids from the living host cell;

contacting the nucleic acids with an amplification reaction mixture, wherein the reaction mixture comprises

a first primer set, comprising the primers of SEQ ID No. 19 and SEQ ID No. 20, and a first probe that provides a first detectable signal upon amplification of a host mitochondrial nucleic acid;

a second primer set, comprising the primers of SEQ ID No. 1 and SEQ ID No. 2, and a second probe that provides a second detectable signal upon amplification of a host nuclear nucleic acid;

amplifying the host mitochondrial nucleic acid and host nuclear nucleic acid by RT-PCR; and

normalizing the first detectable signal to the second detectable signal and comparing the normalized first detectable signal from the living host cell that has been treated with the compound to a normalized first detectable signal from a control host cell that has not been treated with the compound, in order to assess the mitochondrial toxicity of the compound in the living host cell.

2. The method of claim 1 wherein the second probe comprises SEQ ID No. 3.

3. The method of claim 2 wherein the second probe comprises a reporter molecule and a quencher molecule.

4. The method of claim 3 wherein the reporter molecule is FAM and the quencher molecule is TAMRA.

5. The method of claim 1 wherein the first probe comprises SEQ ID No. 21.

6. The method of claim 5 wherein the first probe comprises a reporter molecule and a quencher molecule.

7. The method of claim 6 wherein the reporter molecule is FAM and the quencher molecule is TAMRA.

8. A method for assessing mitochondrial toxicity of an antiviral compound in a living cell from a host, the method comprising:

contacting a living cell from a host with an antiviral compound;

recovering nucleic acids from the living host cell;

contacting the nucleic acids with an amplification reaction mixture, wherein the reaction mixture comprises

a first primer set, comprising the primers of SEQ ID No. 19 and SEQ ID No. 20, and a first probe that provides a first detectable signal upon amplification of a host mitochondrial nucleic acid;

a second primer set, comprising the primers of SEQ ID No. 1 and SEQ ID No. 2, and a second probe that provides a second detectable signal upon amplification of a host nuclear nucleic acid;

amplifying the host mitochondrial nucleic acid and host nuclear nucleic acid by RT-PCR; and

normalizing the first detectable signal to the second detectable signal and comparing the normalized first detectable signal from the living host cell that has been treated with the antiviral compound to a normalized first detectable signal from a control host cell that has not been treated with the antiviral compound, in order to assess the mitochondrial toxicity of the antiviral compound in the living host cell.

9. The method of claim 8 wherein the second probe comprises SEQ ID No. 3.

10. The method of claim 9 wherein the second probe comprises a reporter molecule and a quencher molecule.

11. The method of claim 10 wherein the reporter molecule is FAM and the quencher molecule is TAMRA.

12. The method of claim 8 wherein the first probe comprises SEQ ID No. 21.

13. The method of claim 12 wherein the first probe comprises a reporter molecule and a quencher molecule.

14. The method of claim 13 wherein the reporter molecule is FAM and the quencher molecule is TAMRA.

Assignments (3)
CERTIFICATE OF DOMESTICATION OF PHARMASSET, LTD Recorded Mar 8, 2013
From: PHARMASSET, LTD.
To: PHARMASSET, INC.
Reel/Frame 029943/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2013
From: STUYVER, LIEVEN; OTTO, MICHAEL J.
To: PHARMASSET LTD
Reel/Frame 029951/0305 →
CHANGE OF NAME Recorded Apr 20, 2012
From: PHARMASSET, INC.
To: GILEAD PHARMASSET LLC
Reel/Frame 028081/0686 →